Philip Nelsen, MD
Retina Specialist · Toledo, OHNPI 1982606109
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by AbbVie at 59.9% of the total. Reporting peaked in 2019 at $6,377 and has fallen 80.8% since, to $1,227 in 2025.
Across 118 payments — averaging $87.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Regeneron Healthcare Solutions, Inc.$2K
- Genentech USA, Inc.$450
- Alimera Sciences, Inc.$385
- Apellis Pharmaceuticals, Inc.$375
- Astellas Pharma US Inc$364
- plus $953 from 11 others
What the payments were for
- Consulting fees$6,00058%
- Travel & lodging$240%
- Food & beverage$4,27441%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 9 | $6,192 |
| Regeneron Healthcare Solutions, Inc. | 47 | $1,623 |
| Genentech USA, Inc. | 9 | $450 |
| Alimera Sciences, Inc. | 12 | $385 |
| Apellis Pharmaceuticals, Inc. | 13 | $375 |
| Astellas Pharma US Inc | 6 | $364 |
| Regeneron | 2 | $244 |
| Harrow Eye, LLC | 2 | $213 |
| Biogen | 7 | $157 |
| Mallinckrodt Hospital Products Inc. | 2 | $133 |
| ANI Pharmaceuticals, Inc. | 2 | $44 |
| AstraZeneca | 1 | $43 |
| Coherus Oncology, Inc. | 2 | $42 |
| Bausch & Lomb Americas Inc. | 1 | $33 |
| Baxter Healthcare | 1 | $17 |
| Eyepoint US, Inc. | 1 | $15 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,341 in reported general payments places this provider in the 70th percentile of 69 retina specialist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 76 | $2,324 |
| Ketorolac Tromethamine | 32 | $916 |
| Acetazolamide | 14 | $696 |
| Latanoprost | 37 | $503 |
| Dorzolamide Hcl | 22 | $411 |
| Brimonidine Tartrate | 19 | $278 |
| Ofloxacin | 11 | $124 |
| Timolol Maleate | 19 | $79 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Toledo
- Jonathan BernsteinToledo$8K
- Ira OrgelToledo$2K
- Charles DabbsToledo$319
- Joseph ConeyBeachwood$980K
- Sumit SharmaCleveland$428K
- Aleksandra RachitskayaCleveland$303K
- David MillerBeachwood$299K
- Katherine TalcottCleveland$272K
- Suber HuangCleveland$124K
- Mashal AkhterColumbus$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.